```
Sign in Subscribe
By Ainvest in options-flow —

💊 NAMS Massive $7.5M Bullish Bet - Smart Money Loading Up Before Major Catalysts! 🚀

Whale trade detected: $7.5M institutional position on NAMS. Someone just bet $7.5 MILLION that NewAmsterdam Pharma explodes higher...

🎯 The Quick Take

Someone just bet $7.5 MILLION that NewAmsterdam Pharma explodes higher by December! This monster trade bought 5,000 contracts of deep in-the-money $25 strike calls expiring December 19th - this is 474x larger than typical NAMS trades! With NAMS up 48% YTD at $36.84 and sitting on three massive catalysts in the next 10 days (Q3 earnings Nov 5-6, AHA Scientific Sessions Nov 7-10), smart money is making an aggressive bullish bet right before potential fireworks. Translation: Institutional players are loading up ahead of what could be major positive developments!

📊 Company Overview

NewAmsterdam Pharma Company N.V. (NAMS) is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated:
- Market Cap: $4.04 Billion
- Industry: Pharmaceutical Preparations
- Current Price: $36.84 (near 52-week high of $41.47)
- Primary Focus: Obicetrapib - next-generation cholesterol drug for cardiovascular disease

💰 The Option Flow Breakdown

The Tape (October 30, 2025 @ 12:29:11):

Time Symbol Side Buy/Sell Type Expiration Premium Strike Volume OI Size Spot Option Price
12:29:11 NAMS ASK BUY CALL 2025-12-19 $7.5M $25 5K 0 5,000 $36.84 $15

Option Symbol: NAMS20251219C25

🤓 What This Actually Means

This is an aggressive bullish position on deep in-the-money calls! Here's what went down:

  • 💸 Massive premium paid: $7.5M ($15.00 per contract × 5,000 contracts)
  • 🎯 Deep ITM position: $25 strike with NAMS trading at $36.84 = $11.84 intrinsic value
  • ⏰ Time value: $3.16 remaining with 50 days to expiration
  • 📊 Size matters: 5,000 contracts represents 500,000 shares worth ~$18.4M
  • 🏦 Institutional play: This is NOT retail - this is serious money from institutional players
  • ⚡ Fresh position: Zero open interest means this is a brand new bet placed today

What's really happening here:
This trader is paying a hefty premium for deep ITM calls, which gives them massive delta exposure (essentially controlling 500,000 shares) with limited downside risk. The timing is critical - positioned right before three major catalysts in the next 10 days: Q3 earnings (Nov 5-6), American Heart Association presentation (Nov 7-10). They're betting NAMS rallies significantly by December expiration, with breakeven at $40.00 (8.6% higher).

Unusual Score: 🔥 EXTREME (474x average size, 100th percentile, Z-score 35.18) - This happens maybe once a year for NAMS! We're seeing institutional-sized positioning ahead of major catalysts.

📈 Technical Setup / Chart Check-Up

YTD Performance Chart

NAMS YTD Performance

NewAmsterdam Pharma is up +47.6% YTD with a current price of $38.32. The chart shows a remarkable recovery story - after a brutal 42.8% drawdown to $14.81 in March-April, NAMS has staged an impressive comeback.

Key observations:
- 📈 Monster rally: From $15 lows in April to $40 highs in October - nearly tripling!
- 💹 Catalyst-driven moves: Sharp spikes in March (Phase 3 data), August (EMA validation), October (recent strength)
- 🎢 Volatility: 58.9% annualized vol - this is a high-beta biotech, not a sleepy stock
- 📊 Recent momentum: October surge to near 52-week highs suggests accumulation before catalysts
- 🚀 Volume spikes: Increased activity in past week indicates institutional positioning

Gamma-Based Support & Resistance Analysis

NAMS Gamma Support/Resistance

Current Price: $38.53

The gamma exposure map reveals critical price magnets and walls around current levels. Unlike mega-cap stocks, NAMS has relatively light gamma positioning, creating potential for explosive moves:

🔵 Support Levels (Put Gamma Below Price):
- $35 - Strongest support with 1.47 total gamma exposure (9% below current)
- This is the ONLY major support level showing gamma activity
- Limited put gamma overall suggests bears aren't heavily protected

🟠 Resistance Levels (Call Gamma Above Price):
- $40 - Major resistance with 0.15 call gamma (4% above current)
- $45 - Extended resistance at 0.02 gamma (17% above current)
- Minimal call gamma suggests market makers won't create strong resistance from hedging

What this means for traders:
NAMS has very light options positioning compared to larger stocks, which creates both opportunity and risk. The weak gamma profile means:
- ✅ Less dealer-induced resistance - stock can move freely if buyers/sellers emerge
- ⚠️ Higher volatility potential - no strong gamma walls to dampen moves
- 🎯 $40 is key level - this aligns with the trader's breakeven on this massive call purchase
- 📊 $35 is critical support - breaking below could trigger technical selling

Net GEX Bias: Bearish (0.46 call gamma vs 1.66 put gamma) - BUT this is misleading. The low absolute gamma means market maker hedging flows won't be a major factor. Price will be driven by fundamental catalysts and institutional positioning, not options dynamics.

Implied Move Analysis

NAMS Chart

Options market pricing for upcoming expirations:

  • 📅 Monthly OPEX (Nov 21 - 22 days): ±$7.22 (±19.64%) → Range: $29.57 - $44.02
  • 📅 Quarterly Triple Witch (Dec 19 - 50 days): ±$8.12 (±22.06%) → Range: $28.39 - $45.20

Translation for regular folks:
Options traders are pricing in a 20% move ($7) by November expiration and a 22% move ($8) through December expiration. This is MASSIVE volatility - typical for biotech heading into major catalysts! The market expects fireworks one way or the other.

The December 19th expiration (when this $7.5M trade expires) has an upper range of $45.20 - meaning the market thinks there's a reasonable chance NAMS could hit $45 by then. That would make this trade extremely profitable (breakeven $40, upside unlimited above that).

Critical insight: The implied move completely covers this trade's breakeven at $40. The trader is NOT betting on an outlier move - they're betting NAMS performs within normal expected volatility range but biased to the upside.

🎪 Catalysts

🔥 Immediate Catalysts (Next 10 Days - THIS IS THE SETUP!)

Q3 2025 Earnings - November 5-6, 2025 (6 DAYS AWAY!) 📊

NewAmsterdam will report Q3 2025 results on November 5, 2025 (before market open), with a conference call scheduled for November 6, 2025, at 9:30 AM ET:

  • 📊 Consensus EPS: -$0.36 to -$0.41
  • 💰 Previous Beat: Q2 2025 posted EPS of -$0.15 vs. consensus of -$0.52 - crushing estimates by 71%!
  • 📈 Q2 Revenue: $19.15M vs $1.44M estimate - 1,230% beat! (milestone payments from Menarini partnership)
  • 🎯 Key watch items: European commercialization timeline updates, PREVAIL trial enrollment completion, cash burn rate, regulatory submission progress

Why this matters: NAMS has beaten earnings consistently, and with EMA review underway for European approval, there could be positive updates on regulatory progress or partnership economics.

American Heart Association (AHA) Scientific Sessions 2025 - November 7-10, 2025 🧬

NewAmsterdam will present additional safety and efficacy data from pivotal Phase 3 trials at the 2025 AHA Scientific Sessions in New Orleans:

  • 🎤 Oral Presentation (November 9, 2025, 10:15 AM CT): "CETP Inhibition with Obicetrapib Produces Substantial Reductions in LDL Particles: Pooled Analysis of BROOKLYN and BROADWAY"
  • 📊 Digital Poster (November 10, 2025): Obicetrapib plus ezetimibe combination data
  • 🧠 Significance: AHA is THE premier cardiovascular conference - data presentations here move stocks and influence physician opinions

This is huge: New data from pooled Phase 3 analysis could show even stronger efficacy than individual trials. This is exactly the type of catalyst that drives biotech stocks higher as it validates the drug's mechanism and builds conviction ahead of regulatory approval.

🚀 Near-Term Catalysts (Q4 2025 - Q1 2026)

European Regulatory Approval - Late 2025 to Early 2026 🇪🇺

The European Medicines Agency (EMA) validated Marketing Authorization Applications in August 2025 for both obicetrapib monotherapy and the obicetrapib-ezetimibe fixed-dose combination:

Why this is massive: European approval would be the FIRST regulatory approval for obicetrapib anywhere in the world. This transforms NAMS from a clinical-stage biotech to a commercial-stage company with immediate revenue potential. Approval announcement could trigger 20-30%+ move.

Clinical Data Excellence Supporting Approval 🔬

The Phase 3 data package submitted to EMA is exceptionally strong:

🧪 Major Catalyst - 2026

PREVAIL Phase 3 Cardiovascular Outcomes Trial - Results Expected November 2026 🏆

The PREVAIL trial is the MOST CRITICAL catalyst for NewAmsterdam Pharma's long-term value:

Analyst expectations: 60% probability of success, expecting hazard ratio in 0.6s range - this would represent significant clinical benefit and justify premium pricing.

Why PREVAIL is the ultimate catalyst: This trial will definitively answer whether obicetrapib prevents heart attacks and strokes, not just lowers cholesterol. Positive results would transform a ~$4B market cap company into a potential blockbuster with multi-billion dollar sales potential. This is a binary make-or-break moment 12 months away.

U.S. Regulatory Pathway - Expected 2027 🇺🇸

While no formal FDA submission timeline disclosed, analysts expect U.S. regulatory approval around 2027 following completion of PREVAIL trial:

🧠 Emerging Opportunity - Alzheimer's Disease

Alzheimer's Biomarker Reduction Data - Expansion Potential 🔬

A pre-specified analysis from the BROADWAY trial demonstrated obicetrapib significantly reduced plasma p-tau217 levels (key Alzheimer's biomarker):

This is a sleeper catalyst: If obicetrapib shows cardiovascular benefits in PREVAIL AND demonstrates Alzheimer's prevention potential, the addressable market explodes exponentially. This could be a multi-indication blockbuster.

📱 Additional Pipeline Development

🎖️ Already Happened (Positive Momentum)

Phase 3 Trial Success - 2024 ✅

All three pivotal Phase 3 trials met primary endpoints with flying colors:
- ✅ BROOKLYN trial (HeFH patients)
- ✅ BROADWAY trial (ASCVD patients)
- ✅ TANDEM trial (combination with ezetimibe)

EMA Validation - August 2025 ✅

Marketing Authorization Applications validated and accepted for review - process underway.

🎲 Price Targets & Probabilities

Using gamma levels, implied move data, and upcoming catalysts, here are the scenarios through December 19th expiration:

📈 Bull Case (40% probability)

Target: $45-50

How we get there:
- 💪 Q3 earnings (Nov 5-6) shows positive regulatory progress and strong cash position
- 🚀 AHA presentation (Nov 7-10) reveals even stronger pooled efficacy data than individual trials
- 🇪🇺 Positive signal from EMA review process or announcement of approval timeline acceleration
- 📊 Multiple analyst upgrades following data presentation and earnings beat
- 🤖 Institutional accumulation continues as conviction builds on European launch
- 📈 Breakthrough implied move resistance at $44-45 levels on sustained buying

Key catalysts aligning: This scenario requires strong execution across earnings AND AHA presentation. With Q2 earnings crushing estimates by 71% and proven Phase 3 efficacy, this is NOT unrealistic.

This trade's profit: At $45, the $25 calls would be worth $20 ($15 cost → $20 value = $5 gain per contract × 5,000 = $2.5M profit or 33% return on $7.5M investment)

🎯 Base Case (45% probability)

Target: $38-42 range

Most likely scenario:
- ✅ Solid earnings meeting expectations with no major surprises
- 📊 AHA data presentation reinforces Phase 3 results, doesn't reveal breakthrough findings
- ⚖️ EMA review proceeds normally with no acceleration or concerns
- 🔄 Trading within implied move range, gradual drift higher on de-risking
- 📊 Market digests catalysts, waits for European approval announcement
- 🎯 Approaches $40 breakeven level for this massive call position

This is realistic: Stock continues consolidating gains from recent rally, drifts toward $40 as catalysts validate thesis without creating explosive moves. Trader achieves modest profits but not a home run.

This trade's profit: At $40, the calls worth $15 (breakeven - no profit/loss). At $42, worth $17 ($2 gain × 5,000 contracts = $1M profit or 13% return).

📉 Bear Case (15% probability)

Target: $30-35

What could go wrong:
- 😰 Q3 earnings disappoints with higher cash burn or regulatory setback news
- 📉 AHA presentation data underwhelms or raises safety questions
- ⚖️ EMA review hits snag requiring additional data or delaying timeline
- 💸 Broader biotech sector selloff drags all names lower
- 🇪🇺 European reimbursement concerns emerge
- 🛡️ Key support: Strong put gamma at $35 should limit downside to -10% range

Important note: Even in bear case, the deep ITM calls retain significant intrinsic value. At $35, the $25 calls still worth $10 (vs $15 cost = -$5 loss per contract × 5,000 = -$2.5M or -33% loss). The deep ITM structure limits downside compared to at-the-money or out-of-the-money calls.

💡 Trading Ideas

🛡️ Conservative: Wait for AHA Data Clarity

Play: Stay on sidelines until after Q3 earnings (Nov 5-6) and AHA presentation (Nov 7-10)

Why this works:
- ⏰ Two binary catalysts in next 10 days create significant event risk
- 💸 Implied volatility elevated (58.9%) - options expensive pre-catalysts
- 📊 Stock already up 48% YTD at $38.32 - taking profits off highs
- 🎯 Better entry likely post-catalysts after IV crush reduces premiums
- 📉 Biotech historically volatile around data presentations - wait for dust to settle

Action plan:
- 👀 Watch November 5-6 earnings closely for regulatory timeline, cash position, partnership updates
- 🎯 Monitor November 7-10 AHA presentations for pooled efficacy data strength
- ✅ Look for pullback to $35 gamma support for stock entry if data validates thesis
- 📊 Confirm no negative signals from EMA review process before committing capital

Risk level: Minimal (cash position) | Skill level: Beginner-friendly

⚖️ Balanced: Post-Catalyst Call Spread

Play: After AHA presentation concludes, sell bull call spread February expiration

Structure: Buy $40 calls, Sell $45 calls (Feb 20, 2026 expiration)

Why this works:
- 🎢 IV crush after earnings/AHA makes options cheaper - buy after volatility drops
- 📊 Defined risk spread ($5 wide = $500 max risk per spread)
- 🎯 Targets implied move upper range at $44-45 where resistance exists
- ⏰ 112 days to expiration gives time for European approval announcement catalyst
- 📈 Captures upside if regulatory progress continues without unlimited risk
- 💰 Breakeven around $41-42 is achievable on positive European approval news

Estimated P&L (adjust after seeing post-catalyst IV):
- 💰 Collect ~$1.50-2.00 credit per spread (net debit of $3.00-3.50)
- 📈 Max profit: $150-200 if NAMS at/above $45 at February expiration
- 📉 Max loss: $300-350 if NAMS below $40 (defined and limited)
- 🎯 Breakeven: ~$43-43.50

Entry timing: Wait 2-3 days after AHA presentation for IV to fully collapse

Risk level: Moderate (defined risk) | Skill level: Intermediate

🚀 Aggressive: Mirror the Whale - Buy Deep ITM Calls (HIGH RISK!)

Play: Follow this institutional trade's strategy with smaller size

Structure: Buy $30 calls (Dec 19 expiration) - similar 50-day timeframe, slightly less ITM

Why this could work:
- 🐋 Following smart money that clearly has conviction on near-term catalysts
- 💪 Deep ITM calls provide high delta exposure (act like stock) with capped downside
- ⚡ Multiple catalysts in next 10 days: earnings Nov 5-6, AHA presentation Nov 7-10
- 📊 Strong recent momentum - stock up 48% YTD and approaching 52-week highs
- 🎯 Betting on European approval progress announcement before December expiration
- 🧠 Leverage without margin calls - can't lose more than premium paid

Why this could blow up (SERIOUS RISKS):
- 💥 LARGE CAPITAL COMMITMENT - $30 calls trading around $10-11 each = $1,000+ per contract
- 😱 Binary catalyst risk - negative earnings or AHA data could gap stock down 15-20%
- 📉 Time decay accelerates approaching expiration - theta works against you daily
- ⚠️ Biotech volatility - NAMS has 58.9% annualized vol, can move violently
- 💸 No dividends, no income - pure directional bet with clock ticking
- 🎲 EMA approval could be delayed beyond December - regulatory timelines unpredictable

Estimated P&L (current market):
- 💰 Cost: ~$10-11 per contract (adjust for current bid/ask)
- 📈 Profit scenario: If NAMS hits $45, $30 calls worth $15 = $4-5 gain per contract (40-50% return)
- 📉 Loss scenario: If NAMS drops to $35, $30 calls worth $5 = -$5-6 loss per contract (-50-60% loss)
- ⚠️ Total loss possible: If NAMS below $30, calls expire worthless = -100%
- 🎯 Breakeven: ~$40-41 at expiration

Position sizing: Only risk 2-5% of portfolio maximum. Biotech options can go to zero.

Risk level: HIGH (can lose 100% of premium) | Skill level: Advanced only

⚠️ WARNING: DO NOT attempt this trade unless you:
- Understand biotech binary event risk and can stomach 30-50% swings
- Can afford to lose entire premium if catalysts disappoint
- Have experience with deep ITM options and their behavior
- Recognize this is essentially a leveraged stock bet with expiration pressure
- Won't panic sell on normal -10% volatility (which is common for NAMS)

Safer alternative: Buy small amount of stock instead of options if you like the long-term story but can't handle options volatility.

⚠️ Risk Factors

Don't get caught by these potential landmines:

  • ⏰ Binary catalysts in next 10 days: Q3 earnings (Nov 5-6) and AHA Scientific Sessions (Nov 7-10) create significant volatility risk. Stock could gap 15-20% either direction on data quality. Historical precedent shows biotech can move violently on conference presentations.

  • 💸 Already up 48% YTD with high volatility: Trading at $38.32 after massive rally from $15 lows. 58.9% annualized volatility means this isn't a sleepy stock - daily moves of 5-10% are normal. Limited margin of safety at current levels.

  • 🧪 PREVAIL trial is ultimate make-or-break event (Nov 2026): While European approval is near-term catalyst, the PREVAIL cardiovascular outcomes trial results in November 2026 will definitively determine if obicetrapib prevents heart attacks and strokes. Success probability estimated at 60% - meaningful failure risk exists. Negative PREVAIL would crater stock regardless of European approval.

  • ⚖️ Regulatory uncertainty and timeline risk: While EMA validated applications in August 2025, approval timelines are unpredictable. Review could extend beyond expected late 2025/early 2026 window. Additional data requests or safety questions could delay approval significantly.

  • 💊 Historical CETP inhibitor failures create skepticism: Previous CETP inhibitors (torcetrapib, dalcetrapib, evacetrapib) all failed in clinical development due to safety or efficacy issues. While obicetrapib's profile is differentiated, investors and physicians remain cautious given class history. Any safety signal would trigger severe selloff.

  • 🏥 Competitive landscape and pricing pressure: Competition from generic statins, injectable PCSK9 inhibitors (Repatha, Praluent), and emerging oral PCSK9 blockers. Payers increasingly resistant to high-priced cardiovascular drugs. Pricing and reimbursement concerns could limit commercial potential even with approval.

  • 💰 Company remains unprofitable with cash burn: Negative EPS of -$1.47 (TTM), no revenue from product sales yet. While Q2 2025 showed $19.15M revenue from milestone payments, operating expenses remain high. Cash position of $783.3M (Q2 2025) is strong, but runway dependent on regulatory success.

  • 📊 Gamma profile offers little protection: Unlike mega-cap stocks with heavy options activity, NAMS has minimal gamma positioning (0.46 call gamma, 1.66 put gamma total). This means market makers won't provide natural support through hedging flows. Price discovery will be driven purely by fundamental catalysts and institutional sentiment - creating potential for explosive moves in either direction.

  • 🇪🇺 European commercialization execution risk: While Menarini partnership provides commercial infrastructure, successful European launch requires physician adoption, reimbursement approvals across multiple countries, and effective marketing. Milestone payments of €863M are contingent on commercial success metrics.

  • 🎯 Smart money timing could be early: This $7.5M institutional bet assumes catalysts deliver by December 19th expiration (50 days). If positive developments occur in Q1 2026 instead, this trade could expire before capturing full upside. Options timing is unforgiving - being early is the same as being wrong.

  • 📉 Broader biotech sector vulnerability: Biotech sector highly correlated to interest rates, risk appetite, and clinical trial success rates across industry. A broader sector selloff or negative FDA decisions on other drugs could pressure NAMS regardless of company-specific fundamentals.

🎯 The Bottom Line

Real talk: Someone just dropped $7.5 MILLION on a bullish bet that NAMS rallies by December - this is 474x larger than typical trades! This isn't retail speculation, this is institutional conviction. They're paying a premium for deep ITM calls positioned right before three major catalysts in the next 10 days: Q3 earnings (Nov 5-6), AHA Scientific Sessions data presentation (Nov 7-10).

What this trade tells us:
- 🎯 Sophisticated player expects NAMS to break above $40 by December 19th
- 💰 They're betting on positive near-term catalysts (earnings, AHA data, regulatory progress)
- ⚖️ Deep ITM structure ($25 strike vs $36.84 stock) limits downside while capturing upside
- 📊 Timing suggests conviction that November 2025 catalysts will be positive and move stock materially

If you own NAMS:
- ✅ Hold through upcoming catalysts if you believe in European approval story
- 📊 Consider taking 25-30% profits at current levels ($38-39) to derisk after 48% YTD gain
- ⏰ November 5-10 is critical week - earnings and AHA presentation will validate or challenge thesis
- 🎯 If data disappoints, strong support at $35 (gamma level) provides first safety net
- 🛡️ Set mental stop at $32-33 to protect against breakdown below technical support

If you're watching from sidelines:
- ⏰ Next 10 days are decision time - wait for Q3 earnings (Nov 5-6) and AHA presentation clarity
- 🎯 Pullback to $35 support on profit-taking would be attractive entry point
- 📈 Looking for confirmation of strong Phase 3 pooled data at AHA, positive earnings beat, regulatory timeline progress
- 🚀 Longer-term (6-12 months), European approval catalyst and PREVAIL trial results (Nov 2026) are legitimate re-rating events
- ⚠️ Biotech volatility means 10-20% swings are normal - only play if you can stomach volatility

If you're considering options:
- 🎯 Wait for post-catalyst IV crush before initiating positions (premiums will be cheaper)
- 📊 Bull call spreads offer defined risk exposure if you believe in upside but want protection
- ⚠️ Avoid naked calls unless you're experienced and can afford total loss
- 💡 Stock position safer than options if you like 12+ month story but can't handle binary event risk

Mark your calendar - Key dates:
- 📅 November 5, 2025 (Tuesday) before market open - Q3 2025 earnings report (5 days away!)
- 📅 November 6, 2025 (Wednesday) 9:30 AM ET - Earnings conference call
- 📅 November 9, 2025 (Sunday) 10:15 AM CT - AHA oral presentation: Pooled Phase 3 analysis
- 📅 November 10, 2025 (Monday) - AHA digital poster: Combination therapy data
- 📅 November 21, 2025 - Monthly OPEX (implied range $29.57-$44.02)
- 📅 December 19, 2025 - Expiration date for this $7.5M trade
- 📅 Late 2025 / Early 2026 - Expected European EMA approval decision
- 📅 November 2026 - PREVAIL cardiovascular outcomes trial results (ultimate make-or-break catalyst)

Final verdict: This is a classic "catalyst-driven biotech trade" where institutional money is positioning aggressively ahead of binary events. The next 10 days will be CRITICAL - earnings and AHA presentation will either validate this bullish thesis or trigger significant downside. Unlike mature mega-cap plays, biotech trades on binary outcomes, not gradual trends. The smart money is clearly betting on positive outcomes across multiple near-term catalysts. If you can handle the volatility and binary risk, the setup is compelling. If you can't stomach potential 20-30% moves either direction, stay on the sidelines and watch.

The European approval pathway is real and progressing, the Phase 3 data is strong, and the commercial opportunity is massive ($4.3B peak sales potential). But execution risk remains high, PREVAIL trial success is not guaranteed (60% probability), and biotech investments can go to zero. Only invest what you can afford to lose, and size positions appropriately for your risk tolerance.

Disclaimer: Options trading involves substantial risk of loss and is not suitable for all investors. This analysis is for educational purposes only and not financial advice. Past performance doesn't guarantee future results. The 474x unusual score reflects this specific trade's size relative to recent history - it does not imply the trade will be profitable or that you should follow it. Biotech investments carry unique risks including clinical trial failures, regulatory rejections, and binary event risk. Always do your own research and consider consulting a licensed financial advisor before trading. NAMS is a pre-revenue biotech company with significant execution risk.

About NewAmsterdam Pharma: NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Market cap: $4.04 billion in the Pharmaceutical Preparations industry.

Subscribe to AInvest Option Labs

Don’t miss out on the latest issues. Sign up now to get access to the library of members-only issues.
jamie@example.com
Subscribe